JP2005518811A - 表現型に関連するゲノム全域での配列変化を決定するための方法 - Google Patents

表現型に関連するゲノム全域での配列変化を決定するための方法 Download PDF

Info

Publication number: JP2005518811A
Authority: JP; Japan
Prior art keywords: fragment; nucleic acid; restriction; immobilized; colony
Prior art date: 2002-03-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2003573179A

Other languages

English (en)

Japanese (ja)

Inventor

パスカルマイヤー，

イリアレヴィー，

マニューオステラス，

ロランファリネリ，

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Lynx Therapeutics Inc

Original Assignee

Lynx Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-05

Filing date

2003-03-05

Publication date

2005-06-30

2002-03-05 Priority claimed from GB0205153A external-priority patent/GB0205153D0/en

2003-03-05 Application filed by Lynx Therapeutics Inc filed Critical Lynx Therapeutics Inc

2005-06-30 Publication of JP2005518811A publication Critical patent/JP2005518811A/ja

Status Withdrawn legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 299
239000012634 fragment Substances 0.000 claims abstract description 385
150000007523 nucleic acids Chemical class 0.000 claims abstract description 350
108091008146 restriction endonucleases Proteins 0.000 claims abstract description 177
102000039446 nucleic acids Human genes 0.000 claims abstract description 156
108020004707 nucleic acids Proteins 0.000 claims abstract description 156
108020004414 DNA Proteins 0.000 claims description 218
125000003729 nucleotide group Chemical group 0.000 claims description 130
239000002773 nucleotide Substances 0.000 claims description 129
239000007787 solid Substances 0.000 claims description 90
238000012163 sequencing technique Methods 0.000 claims description 70
230000003321 amplification Effects 0.000 claims description 58
238000003199 nucleic acid amplification method Methods 0.000 claims description 58
238000000137 annealing Methods 0.000 claims description 34
238000006243 chemical reaction Methods 0.000 claims description 33
102000053602 DNA Human genes 0.000 claims description 28
108010042407 Endonucleases Proteins 0.000 claims description 25
238000003776 cleavage reaction Methods 0.000 claims description 17
230000007017 scission Effects 0.000 claims description 17
238000002156 mixing Methods 0.000 claims description 16
238000001514 detection method Methods 0.000 claims description 12
238000009396 hybridization Methods 0.000 claims description 10
102000004533 Endonucleases Human genes 0.000 claims description 9
238000013507 mapping Methods 0.000 claims description 6
230000003100 immobilizing effect Effects 0.000 claims 8
108020004682 Single-Stranded DNA Proteins 0.000 claims 7
230000002068 genetic effect Effects 0.000 abstract description 11
239000013610 patient sample Substances 0.000 abstract description 2
239000013598 vector Substances 0.000 description 69
102000004190 Enzymes Human genes 0.000 description 40
108090000790 Enzymes Proteins 0.000 description 40
230000029087 digestion Effects 0.000 description 40
239000000047 product Substances 0.000 description 35
238000004458 analytical method Methods 0.000 description 31
239000000523 sample Substances 0.000 description 21
102100031780 Endonuclease Human genes 0.000 description 18
108091034117 Oligonucleotide Proteins 0.000 description 17
238000010367 cloning Methods 0.000 description 16
239000013612 plasmid Substances 0.000 description 16
239000011324 bead Substances 0.000 description 15
239000000203 mixture Substances 0.000 description 15
238000000746 purification Methods 0.000 description 14
238000002360 preparation method Methods 0.000 description 13
239000012472 biological sample Substances 0.000 description 12
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 11
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 11
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
238000011049 filling Methods 0.000 description 9
108700028369 Alleles Proteins 0.000 description 8
102000004594 DNA Polymerase I Human genes 0.000 description 8
108010017826 DNA Polymerase I Proteins 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
102000054765 polymorphisms of proteins Human genes 0.000 description 8
102000012410 DNA Ligases Human genes 0.000 description 7
108010061982 DNA Ligases Proteins 0.000 description 7
241000701959 Escherichia virus Lambda Species 0.000 description 7
230000000295 complement effect Effects 0.000 description 7
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 7
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 7
241000894007 species Species 0.000 description 7
239000011543 agarose gel Substances 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000007399 DNA isolation Methods 0.000 description 5
230000008859 change Effects 0.000 description 5
210000000349 chromosome Anatomy 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 5
239000000539 dimer Substances 0.000 description 5
239000011521 glass Substances 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
239000000178 monomer Substances 0.000 description 5
230000008569 process Effects 0.000 description 5
238000011160 research Methods 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
229920000936 Agarose Polymers 0.000 description 4
108020004638 Circular DNA Proteins 0.000 description 4
102000003960 Ligases Human genes 0.000 description 4
108090000364 Ligases Proteins 0.000 description 4
101150101095 Mmp12 gene Proteins 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
239000003550 marker Substances 0.000 description 4
238000010606 normalization Methods 0.000 description 4
102000040430 polynucleotide Human genes 0.000 description 4
108091033319 polynucleotide Proteins 0.000 description 4
239000002157 polynucleotide Substances 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
108091028664 Ribonucleotide Proteins 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
-1 carbocyclic sugars Chemical class 0.000 description 3
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
230000036425 denaturation Effects 0.000 description 3
238000004925 denaturation Methods 0.000 description 3
239000005547 deoxyribonucleotide Substances 0.000 description 3
125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000007850 fluorescent dye Substances 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
239000002336 ribonucleotide Substances 0.000 description 3
125000002652 ribonucleotide group Chemical group 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
230000007018 DNA scission Effects 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
238000013019 agitation Methods 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000013599 cloning vector Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000030609 dephosphorylation Effects 0.000 description 2
238000006209 dephosphorylation reaction Methods 0.000 description 2
208000022602 disease susceptibility Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000003205 genotyping method Methods 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
210000002200 mouth mucosa Anatomy 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108010086093 Mung Bean Nuclease Proteins 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
108010010677 Phosphodiesterase I Proteins 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000239226 Scorpiones Species 0.000 description 1
HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
WRTKMPONLHLBBL-KVQBGUIXSA-N dXTP Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(NC(=O)NC2=O)=C2N=C1 WRTKMPONLHLBBL-KVQBGUIXSA-N 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011901 isothermal amplification Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
238000011068 loading method Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
RXMBKOPBFXCPDD-UHFFFAOYSA-N methoxyphosphonamidous acid Chemical compound COP(N)O RXMBKOPBFXCPDD-UHFFFAOYSA-N 0.000 description 1
238000012775 microarray technology Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000002974 pharmacogenomic effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
238000007480 sanger sequencing Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/301—Endonuclease

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Health & Medical Sciences (AREA)
Analytical Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Physics & Mathematics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pathology (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

JP2003573179A 2002-03-05 2003-03-05 表現型に関連するゲノム全域での配列変化を決定するための方法 Withdrawn JP2005518811A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US36202302P	2002-03-05	2002-03-05
GB0205153A GB0205153D0 (en)	2002-03-05	2002-03-05	Methods for detecting genome-wide sequence variations associated with a phenotype
PCT/GB2003/000941 WO2003074734A2 (fr)	2002-03-05	2003-03-05	Procedes de detection de variations de sequence a l'echelle du genome associees a un phenotype

Publications (1)

Publication Number	Publication Date
JP2005518811A true JP2005518811A (ja)	2005-06-30

Family

ID=27790185

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2003573179A Withdrawn JP2005518811A (ja)	2002-03-05	2003-03-05	表現型に関連するゲノム全域での配列変化を決定するための方法

Country Status (6)

Country	Link
EP (1)	EP1483404A2 (fr)
JP (1)	JP2005518811A (fr)
KR (1)	KR20050008651A (fr)
AU (1)	AU2003208480A1 (fr)
CA (1)	CA2478722A1 (fr)
WO (1)	WO2003074734A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE510024T1 (de)	2003-10-31	2011-06-15	Advanced Genetic Analysis Corp Ab	Verfahren zur herstellung eines gepaarten tag aus einer nukleinsäuresequenz sowie verfahren zur verwendung davon
US20110059865A1 (en)	2004-01-07	2011-03-10	Mark Edward Brennan Smith	Modified Molecular Arrays
US20050176019A1 (en) *	2004-02-10	2005-08-11	Beutel Bruce A.	Method for identification of the location of mutations in whole genomes
WO2006003721A1 (fr) *	2004-07-02	2006-01-12	Kabushiki Kaisha Dnaform	Procede de preparation de marqueurs de sequence
CA2615323A1 (fr)	2005-06-06	2007-12-21	454 Life Sciences Corporation	Sequencage d'extremites appariees
GB0514910D0 (en)	2005-07-20	2005-08-24	Solexa Ltd	Method for sequencing a polynucleotide template
GB0514935D0 (en)	2005-07-20	2005-08-24	Solexa Ltd	Methods for sequencing a polynucleotide template
CN101395281B (zh) *	2006-01-04	2013-05-01	骆树恩	用于核酸作图和鉴定核酸的精细结构变化的方法以及用途
EP1987159B2 (fr)	2006-02-08	2020-08-12	Illumina Cambridge Limited	Procédé de séquençage d'une matrice polynucléotidique
US7754429B2 (en)	2006-10-06	2010-07-13	Illumina Cambridge Limited	Method for pair-wise sequencing a plurity of target polynucleotides
US8551704B2 (en)	2007-02-16	2013-10-08	Pacific Biosciences Of California, Inc.	Controllable strand scission of mini circle DNA
CA2693979A1 (fr) *	2007-07-26	2009-02-05	Pacific Biosciences Of California, Inc.	Sequencage moleculaire redondant
EP2191011B1 (fr) *	2007-08-29	2017-03-29	Illumina Cambridge Limited	Procédé de séquençage d'une matrice de polynucléotides
JP2011509095A (ja)	2008-01-09	2011-03-24	ライフテクノロジーズコーポレーション	核酸配列決定のための対をなすタグのライブラリーを製造する方法
US9540637B2 (en)	2008-01-09	2017-01-10	Life Technologies Corporation	Nucleic acid adaptors and uses thereof
US8202691B2 (en)	2008-01-25	2012-06-19	Illumina, Inc.	Uniform fragmentation of DNA using binding proteins
US12060554B2 (en)	2008-03-10	2024-08-13	Illumina, Inc.	Method for selecting and amplifying polynucleotides
US8541207B2 (en)	2008-10-22	2013-09-24	Illumina, Inc.	Preservation of information related to genomic DNA methylation
LT2669387T (lt)	2009-08-25	2016-10-25	Illumina, Inc.	Polinukleotidų atrankos ir padauginimo būdai
US9012022B2 (en)	2012-06-08	2015-04-21	Illumina, Inc.	Polymer coatings
WO2019005946A2 (fr) *	2017-06-27	2019-01-03	Leighton Bonnie Berger	Externalisation ouverte de génome sécurisée pour études d'association à grande échelle
JP7477183B2 (ja) *	2019-04-22	2024-05-01	ポステック・リサーチ・アンド・ビジネス・ディベロップメント・ファウンデーション	新規な等温単一反応用プローブセット及びその用途
CN114040985A (zh)	2020-03-09	2022-02-11	因美纳有限公司	用于对多核苷酸进行测序的方法
WO2023114397A1 (fr)	2021-12-16	2023-06-22	Illumina, Inc.	Regroupement hybride
WO2023114394A1 (fr)	2021-12-17	2023-06-22	Illumina, Inc.	Hybridation orthogonale
CA3223653A1 (fr)	2022-03-15	2023-09-21	Aathavan KARUNAKARAN	Sequencage simultane de brins de complement avant et inverse sur des polynucleotides separes pour la detection de methylation
US20240352515A1 (en)	2022-03-15	2024-10-24	Illumina, Inc.	Methods of base calling nucleobases
WO2024061799A1 (fr)	2022-09-19	2024-03-28	Illumina, Inc.	Polymères déformables comprenant des amorces immobilisées
US20240102067A1 (en)	2022-09-26	2024-03-28	Illumina, Inc.	Resynthesis Kits and Methods
US20240110221A1 (en)	2022-09-30	2024-04-04	Illumina, Inc.	Methods of modulating clustering kinetics
US20240124914A1 (en)	2022-09-30	2024-04-18	Illumina, Inc.	Thermophilic compositions for nucleic acid amplification
US20240124929A1 (en)	2022-09-30	2024-04-18	Illumina, Inc.	Mesophilic compositions for nucleic acid amplification
US20240110234A1 (en)	2022-09-30	2024-04-04	Illumina, Inc.	Amplification Compositions and Methods
WO2024256580A1 (fr)	2023-06-14	2024-12-19	Illumina, Inc.	Séquençage simultané avec des anneaux spatialement séparés
WO2024256581A1 (fr)	2023-06-14	2024-12-19	Illumina, Inc.	Identification de cytosines modifiées

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU631562B2 (en) *	1988-02-22	1992-12-03	Pioneer Hi-Bred International, Inc.	Genetic linkages between agronomically important genes and restriction fragment length polymorphisms
ATE191510T1 (de) *	1991-09-24	2000-04-15	Keygene Nv	Selektive restriktionsfragmentenamplifikation: generelles verfahren für dns-fingerprinting
US5710000A (en) *	1994-09-16	1998-01-20	Affymetrix, Inc.	Capturing sequences adjacent to Type-IIs restriction sites for genomic library mapping
WO2000014282A1 (fr) *	1998-09-04	2000-03-16	Lynx Therapeutics, Inc.	Procede de depistage de polymorphisme genique
EP1242630B1 (fr) *	1999-12-29	2006-02-01	Keygene N.V.	Methode de generation d'oligonucleotides, plus particulierement de detection de fragments de restriction amplifies obtenus au moyen d'aflp
US6613520B2 (en) *	2000-04-10	2003-09-02	Matthew Ashby	Methods for the survey and genetic analysis of populations

2003
- 2003-03-05 CA CA002478722A patent/CA2478722A1/fr not_active Abandoned
- 2003-03-05 JP JP2003573179A patent/JP2005518811A/ja not_active Withdrawn
- 2003-03-05 AU AU2003208480A patent/AU2003208480A1/en not_active Abandoned
- 2003-03-05 EP EP03706768A patent/EP1483404A2/fr not_active Withdrawn
- 2003-03-05 KR KR10-2004-7013908A patent/KR20050008651A/ko not_active Application Discontinuation
- 2003-03-05 WO PCT/GB2003/000941 patent/WO2003074734A2/fr not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2478722A1 (fr)	2003-09-12
WO2003074734A3 (fr)	2004-02-19
AU2003208480A1 (en)	2003-09-16
KR20050008651A (ko)	2005-01-21
EP1483404A2 (fr)	2004-12-08
WO2003074734A2 (fr)	2003-09-12

Publication	Publication Date	Title
JP2005518811A (ja)	2005-06-30	表現型に関連するゲノム全域での配列変化を決定するための方法
US20070015200A1 (en)	2007-01-18	Methods for detecting genome-wide sequence variations associated with a phenotype
US10978175B2 (en)	2021-04-13	Strategies for high throughput identification and detection of polymorphisms
EP1456407B1 (fr)	2008-12-31	Enrichissement d'acide nucleique
CN114438169B (zh)	2024-11-08	使用CRISPR/Cas系统蛋白靶向消减、富集、和分割核酸的组合物及方法
US6027894A (en)	2000-02-22	Nucleic acid adapters containing a type IIs restriction site and methods of using the same
EP1929039B1 (fr)	2009-12-30	Criblage a haut debit de populations mutagenisees
US5861245A (en)	1999-01-19	Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
DK1991698T3 (en)	2014-03-10	"High-throughput" -sekvensbaseret detection of SNPs using ligeringsassays
US5851762A (en)	1998-12-22	Genomic mapping method by direct haplotyping using intron sequence analysis
CN110139931B (zh)	2024-06-11	用于定相测序的方法和组合物
CN109310784A (zh)	2019-02-05	用于制备和使用指导核酸的方法和组合物
US20040126760A1 (en)	2004-07-01	Novel compositions and methods for carrying out multple pcr reactions on a single sample
JPH08505535A (ja)	1996-06-18	一本鎖ｄｎａ分子の生成方法
CA2087042C (fr)	2006-04-04	Methode de cartographie genomique par haplotypage direct a l'aide de l'analyse de la sequence des introns
IE83464B1 (en)	2004-06-02	Process for amplifying and detecting nucleic acid sequences
IE19930227A1 (en)	1986-09-28	Kit for use in amplifying and detecting nucleic acid sequences

Legal Events

Date	Code	Title	Description
2006-05-09	A300	Application deemed to be withdrawn because no request for examination was validly filed	Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20060509

Date

Code

Title

Description

2006-05-09

A300

Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060509